To determine whether overexpression of TRAF4-mediated chemoresistance was associated with CHK1 activation in CRC cells, we examined the efficacy of a CHK1 inhibitor, prexasertib, in abrogating 5-Fu resistance. This evidence concerns the gene TRAF4 and colorectal carcinoma.